Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04039607 · ClinicalTrials.gov registry record · Phase 3
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 732
- Enrollment target
- 20
- Study locations
NCT04039607: Active Phase 3 study of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.
NCT04039607 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 732 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (190% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04039607, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 732 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Sorafenib
- DRUG lenvatinib
Study Locations (20)
Texas
- Local Institution - 0304 - Dallas
- Local Institution - 0202 - Houston
- Local Institution - 0046 - Lubbock
California
- Local Institution - 0288 - Coronado
- Local Institution - 0157 - Duarte
Michigan
- Local Institution - Ann Arbor
- Local Institution - 0018 - Detroit
Buenos Aires
- Local Institution - 0037 - Caba
- Local Institution - 0194 - Pilar
Other
- Local Institution - 0136 - Buenos Aires
- Local Institution - 0058 - San Miguel de Tucumán
Arizona
- Local Institution - 0292 - Tucson
District of Columbia
- Local Institution - 0077 - Washington D.C.
Kentucky
- Local Institution - 0027 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2026-11-09 |
| Phase | Phase 3 |
What the registry record for NCT04039607 still lists
NCT04039607 is an interventional study that assigns participants to a tested intervention. The registered 732 participants enrollment target is mid-sized for trials with a published cap, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (190% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT04039607 names 20 study sites across 14 states, led by Texas, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT04039607 about?
NCT04039607 is a clinical study titled "A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma". The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
What is the current status of trial NCT04039607?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 732 participants. The study started on 2019-09-30. Estimated completion is 2026-11-09.
What conditions does trial NCT04039607 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT04039607?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Sorafenib (DRUG), lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04039607?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04039607 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04039607's enrollment target sits among peer trials
732 15th of 145 higher than 131 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
-
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI